 | Up a level |
Journal Article
Althoff, K., Leitzke, S., Herling, C., Frenzel, L., Schiller, J., Herling, M., Holtick, U., Scheid, C. and Theurich, S. (2018). Metabolic status and immune activation prior conditioning influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation. Oncol. Res. Treat., 41. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262
Chakupurakal, G., Leitzke, S., Langerbeins, P., Schiller, J., Schneider, P. M., Holtick, U., Shimabukuro-Vornhagen, A., Theurich, S., Chemnitz, J., Hallek, M., von Bergwelt-Baildon, M. and Scheid, C. (2015). Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality-a single institution experience. Ann. Hematol., 94 (10). S. 1717 - 1726. NEW YORK: SPRINGER. ISSN 1432-0584
Gloyer, L., Golumba-Nagy, V, Meyer, A., Yan, S., Schiller, J., Breuninger, M., Jochimsen, D. and Kofler, D. M. (2022). Adenosine receptor A2a blockade by caffeine increases IFN-gamma production in Th1 cells from patients with rheumatoid arthritis. Scand. J. Rheumatol., 51 (4). S. 279 - 284. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1502-7732
Holtick, U., Herling, M., Theurich, S., Frenzel, L., Herling, C., Schiller, J., Hallek, M. and Scheid, C. (2018). A phase II study to investigate the efficacy of short-term everolimus in addition to post-transplant cyclophosphamide as graft-versus-host-prophylaxis after allogeneic hematopoietic stem cell transplantation (OCTET-EVER). Oncol. Res. Treat., 41. S. 63 - 64. BASEL: KARGER. ISSN 2296-5262